The drug candidate that can enhance the effect of chemotherapy


Anna Hultin
Chief office officer
Quisque lacinia magna quis enim ornare eleifend. Ut porttitor sodales nulla non feugiat. Phasellus volutpat, nunc tincidunt molestie rhoncus, mi ipsum tempor elit, nec tempor ipsum augue eu ex. Integer euismod aliquam hendrerit. Sed id sem vestibulum, sollicitudin sapien ut, tristique nulla. Maecenas quis volutpat nunc, a bibendum erat. Integer et turpis risus. Vestibulum viverra, purus sit amet hendrerit hendrerit, lorem dui bibendum lacus, non pellentesque ipsum neque pharetra justo. Aenean a aliquam tellus, in posuere ante. Integer viverra congue urna a sollicitudin.
Holidings:
245 100 shares
171 444 Warrants serie TO1
171 444 Warrants serie TO2
Performance-based share rights 2025-2028
E-mail:
anna.hultin@isofolmedical.com
*Own or related natural or legal person holding shares and other financial instruments in the company. Holdings as of July 31, 2025.
En rubrik
Quisque lacinia magna quis enim ornare eleifend. Ut porttitor sodales nulla non feugiat.
Govurnace repoart
Govurnace repoart
Govurnace repoart
Upcoming Events
- June 09, 2026 - June 09, 2026
The 8th Biotech Hanse Forum, Sweden - August 25, 2026 - August 25, 2026
Interim report April-June 2026 - November 12, 2026 - November 12, 2026
Interim report July-September 2026
| kolumn rubrik 1 | kolumn rubrik 2 | kolumn rubrik 3 | kolumn rubrik 4 |
|---|---|---|---|
| afasdf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf |
| sfasdf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf |
| asfsadf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf | adsfasf asasdfsd adsfasdf adsfsdaf |
Last updated: